medigraphic.com
ISSN 0016-3813 (Impreso)

2008, Número 1

<< Anterior Siguiente >>

Gac Med Mex 2008; 144 (1)


Interferón: 50 años después (1957-2007)

Ramos-Bello D, Ramos-Niembro F

Idioma: Español
Referencias bibliográficas: 137
Paginas: 55-65
Archivo PDF: 86.40 Kb.


RESUMEN

Identificados inicialmente como un mecanismo de defensa contra las infecciones virales, en el transcurso de los últimos 50 años se ha definido que los interferones forman parte de la extensa familia de las citocinas, sustancias indispensables para el funcionamiento del sistema inmunológico. Debido a sus diversas funciones pleiotrópicas, los interferones fueron las primeras citocinas empleadas para el manejo de una amplia gama de padecimientos, propiedades que progresivamente los han colocado como medicamentos de primera elección para el tratamiento de la infección crónica por el virus de la hepatitis B, virus de la hepatitis C, esclerosis múltiple, algunas leucemias, melanoma, etc. No obstante, la administración de dosis suprafisiológicas de interferones con fines terapéuticos, independientemente de su indicación primaria, se han asociado con toxicidad importante, incluyendo la inducción de autoinmunidad y más de 30 enfermedades autoinmunes diferentes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Isaacs A, Burke DC. Viral interference and interferon. Br Med Bull 1959;15:185-188.

  2. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-267.

  3. Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci 1957;147:268-273.

  4. Kalvakolanu DV, Borden EC. An overview of the interferon system: signal transduction and mechanism of action. Cancer Invest 1996;14:25-53.

  5. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55.

  6. Johnson HM, Bazer FW, Szente BE, Jarpe MA. How interferons fight disease. Sci Am 1994;270:68-75.

  7. Theofilopoulus AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/ β) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-336.

  8. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 2005;5:675-687.

  9. Billiau A. Interferon: the pathways of discovery I. Molecular and cellular aspects. Cytokine Growth Factor Rev 2006;17:381-409.

  10. Billiau A. Anti-inflammatory properties of type I interferons. Antiviral Res 2006;71:108-116.

  11. Ho M. Inteferon-like viral inhibitor in rabbits after intravenous administration of endotoxin. Science 1964;146:1472-1474.

  12. Wheelock EF. IFN-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965;141:130-141.

  13. Field AK, Lampson GP, Tytell AA, Nemes MM, Hilleman MR. Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage. USA: Proc Natl Acad Sci 1967;58:2102-2108.

  14. Gresser I. The effect of interferon preparations on friend leukemia of mice. Bibl Haematol 1968;30:37-39.

  15. Gresser I, Berman L, De The G, Brouty-Boye D, Coppey J, Falcoff E. Interferon and murine leukemia. V. Effect of interferon preparations on the evolution of Rauscher disease in mice. J Natl Cancer Inst 1968;41:505-522.

  16. Havell EA, Berman B, Ogburn CA, Berg K, Paucker K, Vilcek J. Two antigenically distinct species of human interferon. USA: Proc Natl Acad Sci 1975;72:2185-187.

  17. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976;295:517-522.

  18. Horoszewicz JS, Leong SS, Ito M, Buffett RF, Karakousis C, Holyoke E, et al. Human fibroblast interferon in human neoplasia: clinical and laboratory study. Cancer Treat Rep 1978;62:1899-1906.

  19. Taniguchi T, Fujii-Kuriyama Y, Muramatsu M. Molecular cloning of human interferon cDNA. USA: Proc Natl Acad Sci 1980;77:4003-4006.

  20. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980;284:316-320.

  21. Knight E Jr, Hunkapiller MW, Korant BD, Hardy RW, Hood LE. Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence. Science 1980;207:525-526.

  22. Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE. Amino terminal sequence of the major component of human lymphoblastoid interferon. Science 1980;207:527-528.

  23. Anonymous. Interferon nomenclature. Nature 1980;286:110.

  24. Jacobs L, O’Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981;214:1026-1028.

  25. Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature 1982;298:859-863.

  26. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl J Med 1983;308:1071-1076.

  27. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15-18.

  28. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985;1:1166.

  29. Burman P, Karison A, Öberg K. Autoimmune thyroid disease in interferon treated patients. Lancet 1985;2:100-101.

  30. Bhakri H, Sriskandan K, Davis T, Pettingale K, Tee D. Recombinant gamma interferon and autoimmune thyroid disease. Lancet 1985;2:457.

  31. Novick D, Orchansky P, Revel M, Rubinstein M. The human IFN-γ receptor. Purification, characterization and preparation of antibodies. J Biol Chem 1987;262:8483-8487.

  32. Aguet M, Merlin G. Purification of human IFN-γ receptors by sequential affinity chromatography on immobilized monoclonal antireceptor antibodies and human IFN-γ. J Exp Med 1987;165;988-999.

  33. Aguet M, Dembic Z, Merlin G. Molecular cloning and expression of the human IFN-γ receptor. Cell 1988;55:273-280.

  34. Calderon J, Sheehan KCK, Chance C, Thomas ML, Schreiber RD. Purification and characterization of the human IFN-γ receptor from placenta. USA: Proc Natl Acad Sci 1988; 85:4837-4841.

  35. Ezekowitz RA, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988;319:146- 151.

  36. Sechler JM, Malech HL, White CJ, Gallin JI. Recombinant human interferongamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. USA: Proc Natl Acad Sci 1988;85:4874-4878.

  37. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-510.

  38. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-1506.

  39. Key LL Jr, Ries WL, Rodriguiz RM, Hatcher HC. Recombinant human interferon gamma therapy for osteopetrosis. J Pediatr 1992;121:119-124.

  40. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992;70:313-322.

  41. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.

  42. Villader-Palacin A. Las citocinas en las enfermedades autoinmunes. Madrid, España: IDEPSA; 1998.

  43. Diaz MO, Bohlander S, Allen G. Nomenclature of human interferon genes. J Interferon Res 1993;13:443.

  44. Sen G, Ransohoff RM. Inteferon-induced antiviral actions and their regulation. Adv Virus Res 1993;42:57-101.

  45. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLRdependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-551.

  46. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.

  47. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32.

  48. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003;39:S93-S98.

  49. Rönnblom L, Eloranta ML, Alm GW. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006;54:408-420.

  50. Grandér D. How does interferon-alpha exerts its antitumor activity in multiple myeloma? Acta Oncologica 2000;39:801-805.

  51. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.

  52. Veldhuis WB, Floris S, van der Meide PH, Vos IM, de Vries HE, Dijkstra CD, et al. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J Cereb Blood Flow Metab 2003;23:1060-1069.

  53. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999;42:90-99.

  54. Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun 1982;11:1-7.

  55. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-674.

  56. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-1408.

  57. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999;53:1397-1401.

  58. Branca AA, Faltynek CR, D’Alessandro SB, Baglioni C. Interaction of interferon with cellular receptors. Internalization and degradation of cell-bound interferon. J Biol Chem 1982;257:13291-1326.

  59. Stark GR, Kerr IM, Williams RB, Silverman RH, Schreiber R. How cells responds to inteferons. Annu Rev Biochem 1998;67:227-264.

  60. Levy DE, Darnell JE Jr. STATs: transcriptional control and biological impact. Nature Rev Cel Biol 2002;3:651-662.

  61. Zwarthohoff EC. Interferon-α In: Roitt IM, Delves PJ. Eds. Encyclopedia of immunology. London: Academic Press; 1992. pp. 886-888.

  62. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219-1226.

  63. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-2499.

  64. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8.

  65. Bengtsoon AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-671.

  66. Dall’era MC, Cardarelli PM, Preston BY, Witte A, Davis JC Jr. Type I interferon correlates with clinical and serologic manifestations of systemic lupus erythematosus. Ann Rheum Dis 2005;64:1692-1697.

  67. Stewart TA. Neutralizing interferon as a therapeutic approach to autoimmune disease. Citokine Growth Factor Rev 2003;14:139-154.

  68. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjogren’s syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-1195.

  69. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-678.

  70. Takii Y, Nakamura M, Ito M, Yokoyama T, Komori A, Shimizu-Yoshida Y, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005;85:908-920.

  71. Jacobsen H. Interferon-β. In: Roitt IM, Delves PJ, editors. Encyclopedia of immunology. London: Academic Press; 1992. p. 889-1.

  72. van Holten J, Smeets TJ, Blankert P, Tak PP. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005;64:1780-1782.

  73. Wheelock EF, Sibley WA. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N Engl J Med 1965;22;273:194-198.

  74. Yip YK, Pang RH, Urban C, Vilcek J. Partial purification and characterization of human gamma (immune) interferon. Proc Natl Acad Sci (USA) 1981;78:1601-1605.

  75. Lawn RM, Gross M, Houck CM, Franke AE, Gray PV, Goeddel DV. DNA sequence of a major human leukocyte interferon gene. Proc Natl Acad Sci (USA) 1981;78:5435-5439.

  76. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-189.

  77. Vilcek J. Interferon-γ In: Roitt IM, Delves PJ. Eds. Encyclopedia of immunology. London: Academic Press; 1992. pp 889-881.

  78. Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol 1995;58:373-381.

  79. Vilcek J, Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004;25:201-209.

  80. http://search.medscape.com/drug-reference-search?newSearch=1&query Text=Interferon

  81. http://www.who.int/mediacentre/factsheets/fs204/en/

  82. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 20055;22:519-528.

  83. Lin OS, Keeffe EB. Current treatment strategies for chronic hepatitis B and C. Annu Rev Med 2001;52:29-49.

  84. http://www.who.int/immunization/topics/hepatitis_c/en/index.html

  85. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.

  86. Kiyosawa K, Sodeyama T, Nakano Y, Yoda H, Tanaka E, Hayata T, et al. Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study. Antiviral Res 1989;12151-12161.

  87. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.

  88. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 2005;72:655-662.

  89. Contessa G, Durelli L. Interferon-beta-1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7:535-542.

  90. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002;53:285-302.

  91. Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007;7:227-239.

  92. Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Josefowicz R, et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986;2:1411-1413.

  93. Gresser I, Bourali C, Levy JP, Fontaine-Brouty-Boye D, Thomas MT. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci (USA) 1969;63:51-57.

  94. Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258-266.

  95. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365-376.

  96. Hurley KE, Chapman PB. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. Oncologist 2005;10:739-742.

  97. Sabel MS, Sondak VK. Is there a role for adjuvant high-dose interferon-alpha- 2b in the management of melanoma? Drugs 2003;63:1053-1058.

  98. Kirkwood JM, Resnick GD, Cole BF. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol 1997;24 (1 Suppl 4):S16-S23.

  99. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002;9:16-21.

  100. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin’s lymphoma. Eur J Cancer 2002;38:1167-1172.

  101. Solal-Celigny P. Increasing treatment options in indolent non-Hodgkin’s lymphoma. Semin Oncol 2002;29(2 Suppl 6):2-6.

  102. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003;16:311-321.

  103. Dummer R, Kempf W, Hess Schmid M, Haffner A, Burg G. Therapy of cutaneous lymphoma-current practice and future developments. Onkologie 2003;26:366-372.

  104. Mellstedt H, Osterborg A, Bjorkholm M, Bjoreman M, Brenning G, Gahrton G, et al. Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. Br J Haematol 1991;79(Suppl 1):21-25.

  105. Anonymous. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. Ann Intern Med 1996;124:212-222.

  106. Guilhot F, Roy L, Martineua G, Guilhot J, Millot F. Immunotherapy in chronic myelogenous leukemia. Clin Lymphoma Myeloma 2007;7(Suppl 2):S64-S70.

  107. Fischl MA, Finkelstein DM, He W, Powderly WG, Triozzi PL, Steigbigel RT. A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi’s sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:379-384.

  108. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi’s sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002;22:295-303.

  109. Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, et al. Treatments of AIDS-related Kaposi’s sarcoma. Crit Rev Oncol Hematol 2005;53:253-265.

  110. De Aloysio D, Miliffi L, Iannicelli T, Penacchioni P, Bottiglioni F. Intramuscular interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection. Acta Obstet Gynecol Scand 1994;73:420-424.

  111. Levine LA, Elterman L, Rukstalis DB. Treatment of subclinical intraurethral human papilloma virus infection with interferon alfa-2b. Urology 1996;47:553-557.

  112. Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferonalpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114:463-471.

  113. Fallani MG, Penna C, Sonni L, Gordigiani R, Cioffi M, Cesario L, et al. Treatment of female genital condylomatosis with intramuscular beta interferon. Minerva Ginecol 1991;43:595-599.

  114. Zarcone R, Bellini P, Cardone G, Cardone A. Treatment of cervix condylomata with alpha-IFN leucocytar. Clin Exp Obstet Gynecol 1995;22:326-329.

  115. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjogren’s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999;19:943-951.

  116. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-593.

  117. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998;129:370-374.

  118. Kötter I, Günaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behçet’s disease: Review of the literature. Semin Arthritis Rheum 2004;33:320-335.

  119. Çalgüneri M, Öztürk MA, Ertenli I, Kiraz , Özbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Behçet’s disease: an open study. Ann Rheum Dis 2003;62:492-493.

  120. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-243.

  121. Ault BH. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988;319;1397-1413.

  122. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety. 1994;10:115-150.

  123. Kausman D, Isenberg DA. Role of biologics in autoimmunity. Lupus 1994;3:461- 466.

  124. Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf 1995;13:371-406.

  125. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995;105:31-57.

  126. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11, 241 patients with chronic hepatitis treated with alfa inteferon. J Hepatol 1996;24:38-47.

  127. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26 (Suppl 1):112S-121S.

  128. Merigan TC. Human interferon as a therapeutic agent. N Engl J Med 1988;318:1458-1460.

  129. Ramos Niembro F. Autoinmunidad y enfermedades autoinumunes asociadas con el empleo de interferones. En: Ramos Niembro F, Orozco Alcalá, Eds.Terapia biológica en las enfermedades reumáticas. México: Elsevier-Masson-Doyma; 2006. pp. 345-368.

  130. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20:3703-3718.

  131. Rönnblom LE, Alm GV, Öberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-183.

  132. Sacchi S, Kantarjian H, O’Brien S, Cohen PR, Pierce S, Talpaz M. Immunemediated and unusual complications during interferon-alpha therapy in chronic myelogeneous leukemia. J Clin Oncol 1995;13:2401-2407.

  133. Papo T. Interferón alpha et auto-immunité. Rev Med Int (Paris). 2002;24(Suppl 4):501s-510s.

  134. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-1442.

  135. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon- á. Autoimmunity 2003;36:511-518.

  136. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718.

  137. Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med 2006;354:758-760.




2020     |     www.medigraphic.com